|
Market Cap | 11.01M | EPS (ttm) | -1.06 |
P/E | - | EPS this Y | 36.67% |
Forward P/E | - | EPS next Y | 40.79% |
PEG | - | EPS past 5Y | -48.36% |
P/S | 0.07 | EPS next 5Y | - |
P/B | 0.21 | EPS Q/Q | 37.68% |
Dividend | - | Sales Q/Q | -6.23% |
Insider Own | 57.23% | Inst Own | 17.86% |
Insider Trans | -7.15% | Inst Trans | -5.63% |
Short Float | 1.42% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 2.75 |
Avg Volume | 108.70K | 52W Range | 0.36 - 2.06 |
|
|
|
BurgerFi International, Inc. engages in the operation of franchised and corporate-owned restaurants. It offers burgers, hotdogs, crispy chicken, frozen custard, hand-cut fries, shakes, beer, and wine. The company was founded by John Rosatti in February 2011 and is headquartered in Fort Lauderdale, FL. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Zavolta Michelle | Chief People Officer | May 09 '24 | Option Exercise | 0.00 | 31,667 | 0 | 38,376 | May 13 08:59 PM | Jones Christopher Emlyn | Chief Financial Officer | Apr 10 '24 | Option Exercise | 0.00 | 67,000 | 0 | 67,000 | Apr 11 04:15 PM | Bachmann Carl J. III | Chief Executive Officer | Apr 10 '24 | Option Exercise | 0.00 | 167,500 | 0 | 294,500 | Apr 11 04:15 PM | JOHN ROSATTI REVOCABLE TRUST | 10% Owner | Mar 25 '24 | Sale | 0.58 | 20,000 | 11,574 | 2,668,396 | Mar 25 09:26 PM | JOHN ROSATTI REVOCABLE TRUST | 10% Owner | Mar 22 '24 | Sale | 0.58 | 20,000 | 11,536 | 2,688,396 | Mar 25 09:26 PM |
|
|
|
|
Market Cap | 21.64M | EPS (ttm) | -0.91 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -19.28% |
P/S | 8.55 | EPS next 5Y | - |
P/B | 3.64 | EPS Q/Q | -28.48% |
Dividend | - | Sales Q/Q | 94245.95% |
Insider Own | 48.80% | Inst Own | 2.37% |
Insider Trans | 0.00% | Inst Trans | 252.73% |
Short Float | 6.70% | Earnings | May 15/b |
Analyst Recom | - | Target Price | - |
Avg Volume | 251.30K | 52W Range | 0.95 - 3.62 |
|
|
|
bioAffinity Technologies, Inc. operates as a development-stage company addressing the significant unmet need for non-invasive, early-stage cancer diagnosis and treatment. The firm develops proprietary in-vitro diagnostic tests and targeted cancer therapeutics using breakthrough technology that preferentially targets cancer cells. The company was founded on March 26, 2014 and is headquartered in San Antonio, TX. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Zannes Maria | President & CEO | Apr 08 '24 | Option Exercise | 1.16 | 64,848 | 75,224 | 229,506 | Apr 24 04:00 PM | Zannes Timothy P | Secretary, EVP, Gen. Counsel | Apr 04 '24 | Option Exercise | 1.16 | 64,848 | 75,224 | 75,155 | Apr 24 04:00 PM | GIRGENTI STEVEN | Director | Apr 03 '24 | Option Exercise | 1.16 | 64,848 | 75,224 | 1,056,606 | Apr 24 04:00 PM | Anderson Robert A. | Director | Feb 26 '24 | Option Exercise | 1.16 | 64,848 | 74,899 | 121,856 | Mar 29 04:52 PM |
|
|
|
|
Market Cap | 558.44M | EPS (ttm) | -0.35 |
P/E | - | EPS this Y | 90.00% |
Forward P/E | 4.79 | EPS next Y | 1065.00% |
PEG | - | EPS past 5Y | -19.31% |
P/S | 3.82 | EPS next 5Y | - |
P/B | 2.10 | EPS Q/Q | -127.83% |
Dividend | - | Sales Q/Q | 71.03% |
Insider Own | 4.71% | Inst Own | 29.33% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 8.27% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 4.63 |
Avg Volume | 22.59M | 52W Range | 0.92 - 3.91 |
|
|
|
Bitfarms Ltd. (Canada) engages in the business of mining cryptocurrency. The firm is also involved in the ownership and operation of server farms comprised of computers designed for the purpose of validating transactions on the Bitcoin blockchain. The company was founded by Emiliano Joel Grodzki and Nicolas Bonta in 2017 and is headquartered in Toronto, Canada. |
|
| |
|
Market Cap | 3.52M | EPS (ttm) | -27.34 |
P/E | - | EPS this Y | 71.22% |
Forward P/E | - | EPS next Y | 17.36% |
PEG | - | EPS past 5Y | 34.89% |
P/S | - | EPS next 5Y | - |
P/B | - | EPS Q/Q | 63.17% |
Dividend | - | Sales Q/Q | - |
Insider Own | 0.23% | Inst Own | 25.29% |
Insider Trans | 0.00% | Inst Trans | 112.18% |
Short Float | 2.84% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 20.00 |
Avg Volume | 1.47M | 52W Range | 2.35 - 44.80 |
|
|
|
Bio-Path Holdings, Inc. is a biotechnology company, which engages in the development of therapies for acute myeloid leukemia (AML) and chronic myeloid leukemia (CML). Its product pipeline includes Prexigebersen, BP1001-A, BP1002, and BP1003. The company was founded by Peter H. Nielsen, Douglas P. Morris, Gabriel Lopez-Berestein and Ana Tari Ashizawa on May 10, 2007 and is headquartered in Bellaire, TX. |
|
|
|
Market Cap | 24.35M | EPS (ttm) | 1.22 |
P/E | 1.27 | EPS this Y | -141.82% |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | - |
P/S | 17.27 | EPS next 5Y | - |
P/B | 0.66 | EPS Q/Q | 710.64% |
Dividend | - | Sales Q/Q | 23.84% |
Insider Own | 44.52% | Inst Own | 4.12% |
Insider Trans | -2.78% | Inst Trans | -1.53% |
Short Float | 0.76% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 3.00 |
Avg Volume | 163.78K | 52W Range | 0.85 - 2.50 |
|
|
|
BTCS, Inc. engages in the digital currency ecosystem and blockchain technologies. It manages an online marketplace where consumers can purchase merchandise using digital currencies such as bitcoin. The company was founded by Timothy Sidie and Michal Handerhan in 2008 and is headquartered in Silver Spring, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Handerhan Michal | COO | Mar 08 '24 | Sale | 1.52 | 69,453 | 105,707 | 1,613,878 | Mar 11 04:01 PM | Handerhan Michal | COO | Mar 07 '24 | Sale | 1.51 | 28,165 | 42,619 | 1,683,331 | Mar 11 04:01 PM | Handerhan Michal | COO | Mar 06 '24 | Sale | 1.51 | 6,844 | 10,323 | 1,711,496 | Mar 06 07:35 PM | Handerhan Michal | COO | Mar 05 '24 | Sale | 1.56 | 45,538 | 70,930 | 1,718,340 | Mar 06 07:35 PM | Allen Charles W | CEO | Feb 20 '24 | Sale | 1.56 | 50,000 | 78,020 | 4,264,220 | Feb 21 05:00 PM |
|
|
| |
|
Market Cap | 593.89M | EPS (ttm) | -1.72 |
P/E | - | EPS this Y | -21.61% |
Forward P/E | - | EPS next Y | -5.50% |
PEG | - | EPS past 5Y | -26.63% |
P/S | - | EPS next 5Y | - |
P/B | 2.76 | EPS Q/Q | -13.60% |
Dividend | - | Sales Q/Q | - |
Insider Own | 13.55% | Inst Own | 95.86% |
Insider Trans | -0.52% | Inst Trans | -19.73% |
Short Float | 25.33% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 33.56 |
Avg Volume | 1.12M | 52W Range | 9.02 - 26.35 |
|
|
|
Cabaletta Bio, Inc. is a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in April 2017 and is headquartered in Philadelphia, PA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Binder Gwendolyn | See Remarks | Jan 19 '24 | Option Exercise | 1.01 | 11,000 | 11,110 | 31,000 | Jan 19 06:30 PM | Binder Gwendolyn | See Remarks | Jan 19 '24 | Sale | 19.59 | 11,000 | 215,439 | 20,000 | Jan 19 06:30 PM | Binder Gwendolyn | See Remarks | Dec 19 '23 | Option Exercise | 1.01 | 11,000 | 11,110 | 31,000 | Dec 19 08:37 PM | Binder Gwendolyn | See Remarks | Dec 19 '23 | Sale | 21.89 | 11,000 | 240,789 | 20,000 | Dec 19 08:37 PM | Binder Gwendolyn | See Remarks | Nov 20 '23 | Option Exercise | 1.01 | 11,000 | 11,110 | 31,000 | Nov 21 04:30 PM |
|
|
|
|
Market Cap | 921.46M | EPS (ttm) | -0.09 |
P/E | - | EPS this Y | 43.70% |
Forward P/E | - | EPS next Y | -9.70% |
PEG | - | EPS past 5Y | -7.69% |
P/S | 104.24 | EPS next 5Y | - |
P/B | 4.25 | EPS Q/Q | -7.83% |
Dividend | - | Sales Q/Q | -82.29% |
Insider Own | 20.67% | Inst Own | 18.91% |
Insider Trans | 104.38% | Inst Trans | -1.05% |
Short Float | 2.92% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 2.22 |
Avg Volume | 4.62M | 52W Range | 0.20 - 1.90 |
|
|
|
Perspective Therapeutics, Inc. is a medical technology and radiopharmaceutical company, which engages in the provision of treatment applications for cancers. The company was founded in 1998 and is headquartered in Seattle, WA. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Austin Mark John | VP Finance/Prin Fin&Acct Offic | Apr 23 '24 | Option Exercise | 0.36 | 30,000 | 10,800 | 84,030 | Apr 24 04:35 PM | Lantheus Alpha Therapy, LLC | 10% Owner | Mar 06 '24 | Buy | 0.95 | 60,431,039 | 57,409,487 | 116,773,394 | Mar 08 11:24 AM | Williamson Robert F III | Director | Jan 30 '24 | Buy | 0.71 | 127,206 | 90,710 | 338,761 | Feb 01 04:53 PM | Williamson Robert F III | Director | Jan 29 '24 | Buy | 0.64 | 25,266 | 16,170 | 211,555 | Jan 30 04:57 PM | Williamson Robert F III | Director | Jan 26 '24 | Buy | 0.56 | 110,613 | 62,304 | 186,289 | Jan 30 04:57 PM |
|
|
| |
|
Market Cap | 203.94M | EPS (ttm) | -3.08 |
P/E | - | EPS this Y | -82.93% |
Forward P/E | - | EPS next Y | -59.00% |
PEG | - | EPS past 5Y | 73.43% |
P/S | 32.07 | EPS next 5Y | - |
P/B | 28.58 | EPS Q/Q | 86.46% |
Dividend | - | Sales Q/Q | - |
Insider Own | 30.68% | Inst Own | 15.59% |
Insider Trans | 0.00% | Inst Trans | -2.34% |
Short Float | 0.91% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 47.50 |
Avg Volume | 31.90K | 52W Range | 4.14 - 26.38 |
|
|
|
CervoMed, Inc. is a clinical stage biotechnology company. It engages in the business of advancing CNS focused therapeutics to benefit patients with a range of degenerative diseases of the brain. The company is currently developing neflamapimod, an investigational orally administered small molecule brain penetrant that inhibits p38MAP kinase alpha. The company was founded in1995 and is headquartered in Boston, MA. |
|
|
|
Market Cap | 13.78M | EPS (ttm) | -0.38 |
P/E | - | EPS this Y | - |
Forward P/E | - | EPS next Y | - |
PEG | - | EPS past 5Y | -37.38% |
P/S | 0.30 | EPS next 5Y | - |
P/B | 0.96 | EPS Q/Q | - |
Dividend | - | Sales Q/Q | 14.07% |
Insider Own | 48.43% | Inst Own | 20.41% |
Insider Trans | 0.00% | Inst Trans | - |
Short Float | 0.36% | Earnings | May 15/b |
Analyst Recom | 1.00 | Target Price | 1.15 |
Avg Volume | 142.32K | 52W Range | 0.17 - 0.96 |
|
|
|
Castellum, Inc. is a technology firm. It operates in the development of strategic acquisitions in cyber security, information technology, information warfare, electronic warfare, software engineering, data analytics and program support. The company was founded on September 30, 2010 and is headquartered in Vienna, MD. |
Insider Trading |
Relationship |
Date |
Transaction |
Cost |
#Shares |
Value ($) |
#Shares Total |
SEC Form 4 |
Fuller Mark C | CEO, President | Jun 13 '23 | Buy | 0.65 | 1,000 | 650 | 7,663,659 | Jun 14 06:01 AM |
|
|
|
|
Market Cap | 1.21B | EPS (ttm) | 1.53 |
P/E | 8.29 | EPS this Y | -2.02% |
Forward P/E | 8.97 | EPS next Y | 16.66% |
PEG | - | EPS past 5Y | - |
P/S | 0.15 | EPS next 5Y | -3.52% |
P/B | 0.97 | EPS Q/Q | 143.28% |
Dividend | 2.54% | Sales Q/Q | -12.05% |
Insider Own | 35.23% | Inst Own | 49.95% |
Insider Trans | 0.00% | Inst Trans | -10.86% |
Short Float | 2.75% | Earnings | May 15/b |
Analyst Recom | 1.50 | Target Price | 15.73 |
Avg Volume | 450.16K | 52W Range | 10.55 - 14.01 |
|
|
|
Dole Plc distributes and markets fresh fruits and vegetables. It operates through the following segments: Fresh Fruit, Diversified Fresh Produce -EMEA, Diversified Fresh Produce - Americas and ROW, and Fresh Vegetables. The Fresh Fruit segment sells bananas and pineapples which are sourced from local growers or Dole-owned and leased farms, predominately located in Latin America, and sold throughout North America, Europe, Latin America, and Asia. The Diversified Fresh Produce - EMEA segment includes Dole's Irish, Dutch, Spanish, Portuguese, French, Italian, U.K., Swedish, Danish, South African, Eastern European and Brazilian businesses, the majority of which sell a variety of imported and local fresh fruits and vegetables through retail, wholesale and, in some instances, food service channels across the European marketplace. The Diversified Fresh Produce - Americas and ROW segment refers to Dole's U.S., Canadian, Chilean, Peruvian, Argentinian and Indian businesses, all which market globally and locally-sourced fresh produce from third-party growers or Dole-owned farms through retail, wholesale, and food service channels. The Fresh Vegetables segment is involved in the operations related to the sale of value-added salads, which include salad and meal kits, and fresh-packed vegetables, which include produce such as iceberg, romaine, leaf lettuces, and celery. The company was founded on June 16, 2017 and is headquartered in Dublin, Ireland. |
|
|